|
|||||
|
|
| 肝细胞癌的分子靶向治疗 | |
| 引用本文： | 张文杰,禄韶英. 肝细胞癌的分子靶向治疗[J]. 世界华人消化杂志, 2011, 0(4) |
| 作者姓名： | 张文杰 禄韶英 |
| 作者单位： | 西安交通大学医学院第一附属医院普通外科; |
| 摘 要： | 肝细胞癌(hepatocellular carcinoma,HCC)是人类第5大恶性肿瘤,死亡率极高.在我国,HCC的治疗已取得显著进展,但总体发病率和死亡率尚无明显改观,对于不适宜手术切除的晚期HCC,现有的药物治疗并不能改善患者预后,进一步提高疗效仍面临严峻挑战.所以,发现新的靶向治疗药物或新的靶点对HCC的早期诊断、化学预防以及治疗显得尤为重要.目前从对HCC发生、发展的分子机制的研究中,人类已发现了多个潜在分子靶点.这些靶点大部分为酪氨酸激酶受体激活的信号传导通路,包括:Raf/MEK/ERK,PI-3K/Akt/mTOR和Jak/Stat等.以索拉菲尼、舒尼替尼等为药物代表的多靶点、多激酶抑制剂治疗HCC更是受到高度关注.本文主要介绍HCC潜在的分子靶点以及常用靶向药物的临床进展. |
| 关 键 词： | 肝细胞癌 分子靶向治疗 索拉菲尼 舒尼替尼 |
Advances in molecularly targeted therapy of hepatocellular carcinoma |
|
| Wen-Jie Zhang,Shao-Yin Lu. Advances in molecularly targeted therapy of hepatocellular carcinoma[J]. World Chinese Journal of Digestology, 2011, 0(4) | |
| Authors: | Wen-Jie Zhang Shao-Yin Lu |
| Affiliation: | Wen-Jie Zhang,Shao-Yin Lu,Department of General Surgery,the First Affiliated Hospital of Medical School of Xi'an Jiaotong University,Xi'an 710061,Shaanxi Province,China |
| Abstract: | Hepatocellular carcinoma(HCC) is a fatal disease that represents the fifth most common human cancer.Although remarkable progress has been achieved in HCC treatment in China,the overall incidence and mortality rates of HCC show no obvious changes.Pharmacological treatment can not improve the prognosis of patients with unresectable HCC.This emphasizes the need to identify new targets for early diagnosis,chemoprevention,and treatment of the disease.An effort to understand the molecular mechanisms responsible f... |
| Keywords: | Hepatocellular carcinoma Molecularly targeted therapy Sorafenib Sunitinib |
| 本文献已被 CNKI 等数据库收录！ | |